MetaCap

Annexon (ANNX) vs Design Therapeutics (DSGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Design Therapeutics (DSGN) has outperformed Annexon (ANNX) over the past year, gaining 8.0% versus a loss of 27.4%. Over five years, DSGN leads with a -49.3% price change compared with -77.4% for ANNX. Annexon is the larger company by market cap ($591.4 million vs $577.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANNX-27.40%DSGN+8.02%
+97%+32%-33%
Nov 21, 20251 yearNov 20, 2026
ANNX-78.09%DSGN-56.02%
+27%-34%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANNX versus DSGN key metrics
MetricANNXDSGN
Share price$3.10$9.02
Market cap$591.37M$577.61M
1-day change-9.09%-3.22%
YTD return-38.25%-3.84%
1-year return-27.40%+8.02%
5-year return-77.37%-49.27%
EPS (TTM)$-1.01$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-206.69M$-69.79M
52-week high$7.18$17.25
52-week low$3.07$8.21
Distance from 52-week high-56.82%-47.71%
Analyst consensusbuystrong_buy
Avg. price target upside+448.39%+139.14%
Average volume3.36M554.69K
Shares outstanding190.76M64.04M
Employees9760
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DSGN has outperformed ANNX by 35.4 percentage points over the past year.

About Annexon

ANNX stock →

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees

About Design Therapeutics

DSGN stock →

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

ANNX vs DSGN FAQ

Which is bigger, Annexon or Design Therapeutics?

Annexon (ANNX) is larger, with a market capitalization of $591.37M compared with $577.61M for Design Therapeutics (DSGN).

Which stock has performed better over the past year, ANNX or DSGN?

DSGN returned +8.02% over the past 12 months, compared with -27.40% for ANNX (price return, excluding dividends). Past performance does not predict future results.

Are Annexon and Design Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons